Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 23, Supplement 1, pp S37–S41 | Cite as

Arterial chemotherapy and transcatheter arterial embolization therapy for non-resectable hepatocellular carcinoma

  • Kenji Hirai
  • Yoshiharu Kawazoe
  • Ken Yamashita
  • Yoshinori Aoki
  • Takafumi Fujimoto
  • Terufumi Sakai
  • Yasuo Majima
  • Masahide Abe
  • Kyuichi Tanikawa
First International Symposium on Treatment of Liver Cancer Kobe, Japan, 15–16 November 1987 Session 2: Chemotherapy, Immunotherapy and Radiotherapy Hepatocellular Carcinoma, Arterial Chemotherapy, Transcatheter Arterial Chemoembolization

Summary

An assessment was made on the therapeutic effects of arterial chemotherapy and transcatheter arterial embolization (TAE) therapy on 378 cases with non-resectable hepatocellular carcinoma (HCC). For the 191 cases who had undergone arterial chemotherapy, 22% had a 1-year survival rate, 8.9% survived for 2 years, and 4.0% for 3 years. Of these, for the 128 cases who were compatible with our criteria for patient selection, the three survival rates were 31.4%, 12.2% and 5.9% respectively. However, for the other 63 cases, who were incompatible with our criteria, the 1-year survival rate was 1.6% and it was worse for the cases who had received supportive care alone. For the cases who had undergone arterial chemotherapy, the highest survival rates were obtained by the alternate administration of different anticancer agents, and the three survival rates were 39.0%, 13.1% and 4.9% respectively. For the 187 cases who had undergone TAE therapy, the 1-year survival rate was 66.2%, the 2-year survival rate 36.5%, and the 3-year survival rate 21.9%. For the 124 cases with a tumor progression rate of less than 20% in the liver (E1), the survival rates were 77.8%, 50.1% and 30.8% respectively. The peripheral venous drug concentrations of mitomycin C and adriamycin were lower, but were maintained for a longer period in TAE therapy than in arterial chemotherapy. These results suggest that consideration of the criteria for patient selection and the alternate administration of anticancer agents are necessary in arterial chemotherapy, and that the best therapeutic effects can be obtained by TAE therapy combined with chemotherapy for cases of non-resectable HCC because of the chemotherapeutic and ischemic effects on the tumors.

Keywords

Survival Rate Anticancer Agent Mitomycin Adriamycin Ischemic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Chan KK, Chlebowski RT, Tong M, Chen HSG, Gross JF, Bateman JR (1980) Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 40: 1263Google Scholar
  2. 2.
    Chen DS, Sheu JC, Sung JL, Lai MY, Lee CS, Su CT, Tsang YM, How SW, Wang TH, Yu JY, Yang TH, Wang CY, Hsu CY (1982) Small hepatocellular carcinoma. A clinicopathological study in thirteen patients. Gastroenterology 83: 1109Google Scholar
  3. 3.
    Hirai K, Kumagai M, Kawazoe Y, Okubo K, Yamaguchi G, Miura T, Tanaka M, Nagasaki Y, Abe M, Kubo Y, Kuriya N, Tanikawa K (1984) Effects of arterial chemotherapy in patients with hepatocellular carcinoma. J Jpn Soc Cancer Ther 19: 1252Google Scholar
  4. 4.
    Iwai K, Maeda H, Konno T (1984) Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 44: 2115Google Scholar
  5. 5.
    Liver Cancer Study Group of Japan (1980) Primary liver cancer in Japan. Cancer 45: 2663Google Scholar
  6. 6.
    Nagasue N (1984) The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 54: 1461Google Scholar
  7. 7.
    Nakamura H, Tanaka T, Hori S, Yoshioka H, Kuroda C, Okamura J, Sakurai M (1983) Transcatheter embolization of hepatocellular carcinoma: Assessment of efficacy in cases of resection following embolization. Radiology 147: 401Google Scholar
  8. 8.
    Nakao N, Miura K, Takahashi H, Ohnishi M, Miura T, Okamoto E, Ishikawa Y (1986) Hepatocellular carcinoma: combined hepatic, arterial, and portal venous embolization, radiology 161: 303Google Scholar
  9. 9.
    Ohnishi K, Tsuchiya S, Nakayama T, Hiyama T, Hiyama Y, Iwama S, Goto N, Takashi M, Ohtsuki T, Kono K, Nakajima Y, Okuda K (1984) Arterial chemoembolization of hepatocellular carcinoma with mitomycin C microcapsules. Radiology 152: 51Google Scholar
  10. 10.
    Ohishi H, Uchida H, Yoshimura H, Ohue S, Ueda J, Katsuragi M, Matsuo N, Hosogi Y (1985) Hepatocellular carcinoma detected by iodized oil. Radiology 154: 25Google Scholar
  11. 11.
    Okamoto E, Tanaka N, Yamanaka N, Kuwata K (1982) Hepatic artery ligation for unresectable hepatocellular carcinoma. Review of 60 cases and long term follow-up results. Acta Hepatol Jpn 23: 1315Google Scholar
  12. 12.
    Okuda K (1986) Early Recognition of Hepatocellular Carcinoma. Hepatology 6: 729Google Scholar
  13. 13.
    Tanikawa K, Hirai K, Kawazoe Y, Yamashita K, Kumagai M, Abe M (1985) One-shot therapy and transcatheter arterial embolization (TAE) therapy for unresectable hepatocellular carcinoma. Jpn J Cancer Chemother 12: 1930Google Scholar
  14. 14.
    Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Kenji Hirai
    • 1
  • Yoshiharu Kawazoe
    • 1
  • Ken Yamashita
    • 1
  • Yoshinori Aoki
    • 1
  • Takafumi Fujimoto
    • 1
  • Terufumi Sakai
    • 1
  • Yasuo Majima
    • 1
  • Masahide Abe
    • 1
  • Kyuichi Tanikawa
    • 1
  1. 1.The Second Department of MedicineKurume University School of MedicineKurume-shi, Fukuokan-kenJapan

Personalised recommendations